Navigation Links
Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
Date:4/21/2009

d our knowledge and understanding of the unique characteristics of our proprietary platinum prodrug," commented Jeffrey B. Davis, Access' President & CEO. "Following the recent announcement of positive results from the completed phase 2 clinical study in patients with recurrent ovarian cancer, and from in vitro data reported previously showing that the anticancer properties of ProLindac are enhanced when used in combination with other anticancer drugs, Access is manufacturing additional supplies of ProLindac for planned combination studies later this year."

Access currently has two development and commercialization partners for ProLindac. A licensing agreement with Jiangsu Aosaikang Pharmaceutical Co., Ltd. ("ASK") was signed in 2008 under which ASK will manufacture, develop and commercialize ProLindac for the Greater China Region which includes the People's Republic of China. In February 2009, Access announced it had signed a licensing agreement with JCOM, Ltd for South Korea for both ProLindac and MuGard, its FDA approved therapy for oral mucositis. Under these licensing agreements, Access receives milestone payments and royalties on sales. Access is currently in discussion with potential partners for development and commercialization of ProLindac in additional territories.

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' prod
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
2. New organic material may speed Internet access
3. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
4. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
5. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
6. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
7. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
8. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology
11. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
(Date:7/31/2014)... 2014 Senomyx , Inc. (NASDAQ: ... proprietary taste science technologies to discover, develop, and ... and ingredient supply industries, today reported financial results ... the second quarter with $33.6 million in cash ... the past quarter Senomyx achieved another important milestone ...
(Date:7/31/2014)... and SHENZHEN, China , July ... today the purchase of an Irys™System by ... selected BioNano,s platform to enable comprehensive exploration of human ... for various organisms of interest, including those where no ... together to develop new methods for multiplexing on the ...
(Date:7/31/2014)... Diego, CA (PRWEB) July 31, 2014 ... announced today the integration of Omicsoft’s Array Suite with ... both platforms will be able to send data in ... integration works with all versions of tranSMART including the ... the art statistics, visualization and storage for the analysis ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... May 25, 2011 Otonomy, Inc., ... for diseases and disorders of the inner and ... Wroblewski as the company,s chief operations officer.  Mr. ... the areas of manufacturing, product supply chain management, ...
... Lund, Sweden, researchers can study a wide range of different ... This could be useful for both basic research and industry ... DanishSwedish collaboration. Now it is opening for research. The ... is used to examine the components of materials and their ...
... Spherix Incorporated (NASDAQ: SPEXD) – an ... syndrome and atherosclerosis, and providers of technical and ... pharmaceutical companies – today announced that it has ... concerns minimum bid price listing requirements. ...
Cached Biology Technology:Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 2Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 3New beamline at MAX II opens for research 2Spherix Regains Compliance With NASDAQ Listing Rule 2
(Date:7/31/2014)... available in German . ... gases similar to a sponge that soaks up liquids. ... hydrogen or greenhouse gases. However, loading of many MOFs ... Technology (KIT) now report in Nature Communications ... MOF surface. This can be prevented by water-free synthesis ...
(Date:7/31/2014)... better identify and treat those with fibromuscular dysplasia (FMD). ... sized arteries in the body, which can restrict blood flow ... new report appearing in August 2014 issue of ... FMD may not be limited to the arteries as currently ... bones and joints, as well as evidence that inflammation may ...
(Date:7/31/2014)... found that bacteria in the Gulf of Mexico consumed ... during the Deepwater Horizon spill in the months after ... In two new studies conducted in a deep sea ... bacteria called Colwellia likely consumed gaseous hydrocarbons ... were released as part of the oil spill. ...
Breaking Biology News(10 mins):Free pores for molecule transport 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... in soils are as diverse in the tropical forests of Costa ... the tundra and boreal forests of Alaska and Sweden. That ... Proceedings of the National Academy of Sciences . Scientists ... found above ground at the equator than at the Earth,s poles. ...
... series are already enjoying the advantages of synthetic blood. While ... big screen, the true benefits of blood manufactured from embryonic ... It is unclear however whether society can develop an acceptance ... produced by related technology. For this reason it is ...
... WASHINGTON and LONDON On the heels of a ... D.C., leaders of the U.S. National Academy of Sciences and ... global insurance and reinsurance broker headquartered in the U.K., pledged ... financial resilience of populations to extreme events. Although 2011 ...
Cached Biology News:From tropics to poles: Study reveals diversity of life in soils 2Can we share vampires' appetite for synthetic blood? 2US science academy and global reinsurance broker spark 2US science academy and global reinsurance broker spark 3US science academy and global reinsurance broker spark 4
...
... HighSens reagents and supplies, for 10 ... sufficient to perform high-sensitivity RNA analysis ... the Experion automated electrophoresis system. Supplied ... microliters RNA HighSens stain, 20 microliters ...
... solid. PROTECT FROM LIGHT. PACKAGED UNDER ... that acts as a selective, reversible ... (IC 50 = 4 μM ... and PTP1B 298 , respectively). ...
...
Biology Products: